Big Buttons

• FDA doubles down: Tirzepatide is off shortage

  ...but that doesn't mean the issue is completely settled. read more →

• A couple of state updates

  Good news from Alabama, but a problem in Massachusetts read more →

• Defending GLP-1 compounding

  The latest letters APC's been sending to oppose efforts to restrict compounding read more →

• Thumbs-up for FDA crackdown

  APC was thrilled when the FDA announced it was taking action against illegal online businesses claiming to sell “research-grade” compounds. read more →

• A PANS/PANDAS explainer

  For your patients: Information about a couple of underdiagnosed pediatric mental health conditions read more →

• What, a year?

  In the final board chair column of the year, here are our top 7 accomplishments in 2024. read more →

• “Simply not a rational approach to regulating an industry”

  This week APC offered its final (and pointed) suggestions to the California Board of Pharmacy on their proposed significant – and we would say unjustified – changes to their compounding regulations. read more →

• Get a cease and desist letter from Verrica?

  APC has heard reports from several pharmacies that have received them — here's what to know. read more →

More News

The FDA released a ruling on Thursday declaring that tirzepatide is, in fact, no longer in shortage — a decision it said was based on Eli Lilly’s “detailed information and data regarding its production and inventory of these drug products at various points in time.”

So it’s official: There is apparently — per Lilly and now the FDA — plenty of Mounjaro and Zepbound to go around. “The information provided in Lilly’s submissions demonstrate that the company is currently meeting or exceeding demand for Mounjaro and Zepbound.”

This doesn’t mean you must immediately stop compounding tirzepatide. The FDA did throw compounders a bone: a 60-day “off-ramp” for 503A compounders (i.e., until Feb. 18, 2025); 90 days for 503Bs (i.e., until Mar. 19, 2025).

All that said, we don’t think the tirzepatide situation is over. Read CEO Scott Brunner’s statement on the FDA decision. Perhaps it can be summed up thusly: “Today’s statement from the agency certainly informs that litigation, but it’s not a decision by a court.”